Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Novartis pipeline in Phase 3
Solid Tumors
Code
AAA617
Conclusions
Appendix
Innovation: Clinical trials
Hematology
References
Abbreviations
INNOVATION
8 lead indications
Lead indication
Mechanism
BCR-ABL inhibitor
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
Indication(s)
Chronic myeloid leukemia, 1st line
Radiation sickness syndrome
Paroxysmal nocturnal hemoglobinuria
Atypical hemolytic uraemic syndrome
Myelodysplastic syndrome
1L Immune Thrombocytopenia
2L Immune Thrombocytopenia
warm Autoimmune Hemolytic Anemia
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
Name
Mechanism
Indication(s)
Pluvicto™
Radioligand therapy target PSMA mCRPC, pre-taxane
Metastatic hormone sensitive prostate cancer (mHSPC)
AAA6011
LutatheraⓇ
BYL719
JDQ443
LEE011
NIS793
Piqray®
JDQ443
Kisqali®
niseovkitug
PI3Ka inhibitor
KRAS inhibitor
TGFB1 inhibitor
VDT482
tislelizumab
PD1 inhibitor
CDK4/6 Inhibitor
Ovarian cancer
2/3L Non-small cell lung cancer
HR+/HER2- BC (adj)
Code
Name
ABL001
ETB115
ScemblixⓇ
PromactaⓇ
LNP023
iptacopan
MBG453
VAY736
sabatolimab
ianalumab
TIM3 antagonist
BAFF-R inhibitor
Adj/Neo adj. NSCLC
1L Gastric cancer
1L Metastatic pancreatic ductal adenocarcinoma
1L Nasopharyngeal Carcinoma
1L ESCC
Immunology
Code
Name
AIN457
IGE025
LOU064
Cosentyx®
XolairⓇ
remibrutinib
QGE031 ligelizumab
VAY736 ianalumab
Name
Mechanism
IL17A inhibitor
IgE inhibitor
BTK inhibitor
IgE inhibitor
BAFF-R inhibitor
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
1L Hepatocellular Carcinoma
1L Urothelial Cell Carcinoma
Indication(s)
Lupus Nephritis
Giant cell arteritis
Polymyalgia rheumatica
Rotator cuff tendinopathy
Food allergy
Chronic spontaneous urticaria
Food allergy
Sjögren's
Lupus Nephritis
Systemic lupus erythematosus
Neuroscience
Code
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 Kesimpta®
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
Localized ESCC
1L Small Cell Lung Cancer
Cardiovascular
Code Name
KJX839 Leqvio®
Mechanism
siRNA (regulation of LDL-C)
Indication(s)
CVRR-LDLC
Primary prevention
Hyperlipidemia, pediatrics
IgA nephropathy
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
LNP023 iptacopan
CFB inhibitor
TQJ230 pelacarsen
ASO targeting Lp(a)
Others
Code
Global Health
COA566 Coartem®
Ophthalmology
RTH258 BeovuⓇ
Biosimilars
Name
Mechanism
Indication(s)
PGH-1 (artemisinin combination Malaria, uncomplicated (<5kg patients)
therapy)
VEGF inhibitor
Code
Name
GP2411 denosumab
SOK583 aflibercept
Mechanism
anti RANKL mAb
VEGF inhibitor
Diabetic retinopathy
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
1. 177 Lu-dotatate in US.
37 Investor Relations | Q1 2023 Results
U NOVARTIS | Reimagining MedicineView entire presentation